Favorable response of ADHD with giant SEP to extended-release valproate.
We treated three boys with attention deficit/hyperactivity disorder (ADHD) associated with giant somatosensory evoked potentials (SEP). All responded well to extended-release valproate (EVA), a gamma-aminobutyric acid (GABA) enhancer. Improvement particularly involved hyperactivity and impulsivity. When methylphenidate previously was administered to two patients, symptoms worsened. EVA therefore may be preferable for ADHD with giant SEP.
Miyazaki
Masahito
M
Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate, Tokushima, Japan. mat@lilac.ocn.ne.jp
Ito
Hiromichi
H
Saijo
Takahiko
T
Mori
Kenji
K
Kagami
Shoji
S
Kuroda
Yasuhiro
Y
D000293:Adolescent; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D016503:Drug Delivery Systems / Q000379:methods; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use*
D000927:Anticonvulsants; D014635:Valproic Acid